Staidson Beijing Biopharma (300204) — Capital Reinvestment Ratio
Staidson Beijing Biopharma (300204) has a Capital Reinvestment Ratio of 1.01x as of March 2020, meaning it reinvests 1% of its operating cash flow (CN¥26.92 Million) in capital expenditures (CN¥27.14 Million). Check tangible net worth ratio of Staidson Beijing Biopharma to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Staidson Beijing Biopharma Capital Reinvestment Ratio (2007–2019)
This chart tracks Staidson Beijing Biopharma's Capital Reinvestment Ratio across 13 annual periods. For the full cash flow conversion analysis, see Staidson Beijing Biopharma (300204) cash flow conversion.
Annual Capital Reinvestment Ratio for Staidson Beijing Biopharma (2007–2019)
Year-by-year Capital Reinvestment Ratio for Staidson Beijing Biopharma from 2007 to 2019. See Staidson Beijing Biopharma free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 1.35x | CN¥44.34 Million | CN¥59.91 Million | ▲ +133.6% |
| 2018 | 0.58x | CN¥165.08 Million | CN¥95.46 Million | ▲ +239.9% |
| 2017 | 0.17x | CN¥273.64 Million | CN¥46.55 Million | ▲ +36.7% |
| 2016 | 0.12x | CN¥212.55 Million | CN¥26.45 Million | ▲ +20.0% |
| 2015 | 0.10x | CN¥231.01 Million | CN¥23.95 Million | ▲ +48.2% |
| 2014 | 0.07x | CN¥206.85 Million | CN¥14.47 Million | ▼ -66.2% |
| 2013 | 0.21x | CN¥111.36 Million | CN¥23.02 Million | ▼ -68.3% |
| 2012 | 0.65x | CN¥90.19 Million | CN¥58.88 Million | ▼ -32.7% |
| 2011 | 0.97x | CN¥87.01 Million | CN¥84.35 Million | ▼ -24.7% |
| 2010 | 1.29x | CN¥63.91 Million | CN¥82.25 Million | ▲ +313.3% |
| 2009 | 0.31x | CN¥42.37 Million | CN¥13.19 Million | ▼ -69.9% |
| 2008 | 1.04x | CN¥16.23 Million | CN¥16.81 Million | ▲ +1535.6% |
| 2007 | 0.06x | CN¥5.41 Million | CN¥342.40K | — |